Matjaz Barboric, PhDUniversity of Helsinki 2020 James A. Harting Pilot Study Award Targeting transcriptional kinases for novel ovarian cancer therapies Ovarian cancer is the deadliest gynecological cancer. Identifying druggable Achilles’ heels of ovarian cancer can lead to new treatments. In order to do this, Dr. Barboric will target critical enzymes called cyclin-dependent kinases (tCDKs) which […]
Read More
Matjaz Barboric, PhDUniversity of Helsinki Role of mutations in transcription elongation Cdk12/CycK kinase in ovarian cancer Better understanding of molecular mechanisms contributing to the onset of high-grade serous ovarian cancer will advance improvements in diagnosis and treatment. Dr. Barboric will investigate the deregulation of a novel transcription elongation kinase Cdk12/CycK, whose recurrent mutations have been […]
Read More
Matjaz Barboric, PhDUniversity of Helsinki Examining the Tumor Suppressor Function of Cdk12/CycK Kinase in Ovarian Cancer Failure to understand key mechanisms contributing to the onset of high-grade serous ovarian cancer represents a barrier to diagnosis and treatment of this fifth-leading cause of death among American women. One of the likely factors promoting the disease is […]
Read More